Skip to main content

Table 1 Main epidemiological and clinical features of the discovery and validation patient cohorts

From: Genome-wide pathway analysis identifies VEGF pathway association with oral ulceration in systemic lupus erythematosus

Clinical and epidemiological variablesa Discovery cohort Validation cohort P
Genetic background CEU CEU -
Number of individuals (N) 482 425 -
Gender (% females) 443 (91.91%) 398 (93.65%) 0.37
Average age at onset (m ± SD) 33.50 ± 14.09 32.39 ± 13.32 0.22
Malar rash (N +/N -) 185/174 183/175 1.00
Discoid rash (N +/N -) 46/313 49/309 0.74
Photosensitivity (N +/N -) 191/168 173/185 0.20
Oral ulcers (N +/N -) 153/206 172/186 0.15
Arthritis (N +/N -) 275/84 267/91 0.54
Serositis (N +/N -) 110/249 122/236 0.34
Renal disorder (N +/N -) 120/239 108/250 0.38
Neurologic disorder (N +/N -) 25/334 35/293 0.10
Hematologic disorder (N +/N -) 341/18 337/21 0.63
Immunologic disorder (N +/N -) 289/70 292/66 0.77
Antinuclear antibodies (N +/N -) 346/13 347/11 0.84
  1. Abbreviations: CEU Caucasian European, M mean, N sample size, N + sample size of positive individuals for the clinical variable, N - sample size of negative individuals for the clinical variable, P P value, SD standard deviation
  2. aNumber of individuals shown in the table represents the total number of patients that were initially recruited for the present study. Conversely, the sample size of positive/negative individuals for the indicated clinical phenotype represents the final number of SLE patients having data on both genotype and phenotype available for association analysis
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us